Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Nieto Barbero (Madrid, Spain), F. Gonzalez-Gamiz (Madrid, Spain), M. Rodríguez-Nieto (Madrid, Spain), S. Sanchez (Alcaá de Henares, Spain), J. Gaudo (Madrid, Spain), C. Valenzuela (Madrid, Spain), B. López-Muñíz (Madrid, Spain), L. Gomez-Carrera (Madrid, Spain), R. Laporta (Majadahonda, Spain), Á. Casanova (Coslada, Spain), M. Río (Getafe, Spain), R. Neumomadrid (Madrid, Spain). Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments. 1301

Member's Comments

No comment yet.

Related content which might interest you: Antifibrotic choice in idiopathic pulmonary fibrosis Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside Year: 2017 Factors affecting the compliance to antifibrotic treatment in patients with interstitial pulmonary fibrosis Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019 Year: 2019 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Current and future therapeutic approaches in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: 693-703 Year: 2005 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019 Year: 2019 Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF treatment II Year: 2016 Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Non-pulmonary comorbidities in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Evaluating disease severity in idiopathic pulmonary fibrosis Source: Eur Respir Rev, 26 (145) 170051; 10.1183/16000617.0051-2017 Year: 2017 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 36: 695-696 Year: 2010 Pirfenidone in idiopathic pulmonary fibrosis Source: Eur Respir J 2010; 35: 821-829 Year: 2010 Predictors of effects and adverse effects of pirfenidone on idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012 The potential impact of azithromycin in idiopathic pulmonary fibrosis Source: Eur Respir J, 53 (2) 1800628; 10.1183/13993003.00628-2018 Year: 2019 Clusters of comorbidities in idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020